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Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are potentially life-
threatening, immune-mediated adverse reactions characterized by widespread erythema, 
epidermal necrosis, and detachment of skin and mucosa. Efforts to grow and develop functional 
international collaborations and a multidisciplinary interactive network focusing on SJS/TEN as 
an uncommon but high burden disease will be necessary to improve efforts in prevention, early 
diagnosis and improved acute and long-term management. SJS/TEN 2019: From Science to 
Translation was a 1.5-day scientific program held April 26-27, 2019, in Vancouver, Canada. The 
meeting successfully engaged clinicians, researchers, and patients and conducted many 
productive discussions on research and patient care needs. 
 
KEYWORDS (6 terms)- Stevens-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN), 
Human leukocyte antigen (HLA), Pharmacogenomics, Pharmacovigilance, Severe cutaneous 
adverse reaction (SCAR) 
 
INTRODUCTION 
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are severe, life-threatening, 
and mainly drug-induced cutaneous adverse reactions, causing blistering, mucosal sloughing 
and epidermal necrosis. The global clinical and financial burden of SJS/TEN is considerable, 
resulting in prolonged hospital stays, mortality of up to 50% in the elderly and considerable 
long-term multi-system physical and mental health morbidity that is still poorly understood 
qualitatively and quantitatively [1]. The last 15 years have seen significant advancements in our 










understanding of the immunopathogenesis and genetic risk factors for SJS/TEN that have fueled 
preventive efforts leading to successful pre-prescription screening programs in some countries 
[2–5]. Research progress requires a collective effort to advance and translate science into 
prediction, prevention, earlier diagnosis and more targeted and effective treatments that will 
lead to improved short and long-term patient outcomes.  
 
The SJS/TEN 2019 meeting built upon the outcomes and success of a 2015 workshop [6] and 
the inaugural SJS/TEN 2017 meeting [1] by further expanding the multidisciplinary engagement 
and communication between Networks and participants. Cutting-edge research and treatment 
presentations, interactive discussions, and breakout sessions were featured to present the 
recent advances and provide a global context of SJS/TEN. This article is a summary of the 
proceedings of the conference that brought together healthcare providers, researchers, 
regulators, government agencies and funders, as well as patients and families in a 1.5-day 
networking meeting to define strategies for multidisciplinary collaboration to address critical 
research gaps and improve SJS/TEN outcomes.  
 
Pharmacogenomic Network and Panel Discussion 
An opening plenary from Neil Shear provided a thoughtful perspective on the past, present, and 
future of the SJS/TEN research. Dr. Shear emphasized the “just do” aspect of implementation 
science necessary to move research and translation forward and the critical nature of 
teamwork in building global research networks. A pharmacogenomics panel was made up of 
diverse stakeholders from six different countries. The panel covered a wide range of topics but 










highlighted that regulations aimed at facilitating the routine clinical use of pharmacogenomics 
should follow evidence-based science and that diverse groups should be involved in these 
decisions. It was also mentioned that health economic and social science studies are 
increasingly important, as well as improving pharmacogenomic decision support systems and 
turnaround times. Finally, these systems should be dynamic, to allow for the inclusion of new 
biomarkers as they are discovered and replicated, and that the community should explore the 




Regional Networks and Registries  
Nine representatives from regional or international networks and registries focused on studies 
associated with severe immune-mediated adverse reactions and shared recent progress in the 
field of SJS/TEN (Figure 1). These leading groups have committed time and energy to 
establishing strong networks to facilitate prospective studies of genetic and mechanistic basis 
and provide an evidence base for treatment approaches. This has included the implementation 
of post-marketing safety surveillance systems and patient health information paired with the 
development of biological banks to store DNA, RNA, PBMCs and tissue samples. The risk of 
SJS/TEN has significant racial/ethnic disparities across drugs used and risk. Currently, Asians 
have been reported as a significantly affected population where much progress has been made 
on the discovery of etiologic genetic markers; however, the burden of TB-HIV co-infection in the 
Unmet need: To build a global research network and develop consensus on the 
implementation of pharmacogenomic testing in order to improve the prevention and 
treatment of SJS/TEN. 










African continent is high and the incidence of SJS/TEN and associated genetic risk factors have 




Clinical Approaches and Management  
The clinical approach to the management of SJS/TEN is multidisciplinary, including 
dermatologists, burn surgeons, ophthalmologists, gynecologists, pharmacologists, 
immunologists, psychiatrists, pharmacists, and other healthcare providers, involved in 
rehabilitation as indicated by the clinical case.  
 
Diagnosis of SJS/TEN is critical to optimal management and subsequent outcomes analysis. 
Recent work has highlighted that up to 1/3 cases may be misdiagnosed, which emphasizes the 
importance of gaining histological confirmation from a skin biopsy at the outset of the rash [7].  
The management of SJS/TEN should be undertaken in specialized centers with capabilities for 
complex skin care and appropriate intensive care for more severe cases, such as dermatology 
departments or burn units, which has been shown to improve outcomes [8]. Although stopping 
the culprit drug is associated with a better prognosis, every day of delay also worsens the 
outcomes [9]. However, identification of the causal drug can be challenging particularly acutely 
and currently relies mainly on expert judgment and clinical causality assessment. Further 
research is critical to develop better ways of “immunophenotyping” patients such as with novel 
Unmet need:  Coordination of research networks to coordinate mechanistic, genetic and 
treatment studies across ethnically diverse populations. 
 
 










validated biomarkers, immunoassays and genetic studies for acute identification of the causal 
drug. 
 
Acute active management is controversial, and there is little consensus on medical 
interventions because of the lack of high-level evidence that any treatment (such as steroids 
and IVIg) is superior to supportive care alone.  Newer treatments such as etanercept (TNF-α 
receptor antagonist) and cyclosporine (calcineurin inhibitor, immunosuppressant) have shown 
promise in a recent non-blinded randomized controlled study (etanercept) and several 
observational studies (cyclosporine and etanercept) [10,11]. Information on the management 
of children versus adults is also lacking given that a much higher proportion of cases in children 
are mediated by infectious and non-drug triggers. However, recent guidelines are useful for 
clinicians if such cases arise [12].  
 
In management of the skin, there is consensus about the important need for non-adherent 
dressings and generous and frequent application of paraffin emollient. While some centers 
undertake debridement of blistered areas, others do not recommend this approach, and the 
issue remains a source of disagreement [13]. This would be a high priority area to address with 
future research, so that the field can develop a unified approach to skin care. Urogynecologic 
manifestations of SJS/TEN warrant further attention as evidenced by the fact that scarring and 
stenosis arise in 18-28% of cases [14,15]. All female patients of SJS/TEN should be seen by a 
gynecologist early where interventions including topical corticosteroid therapy, catheterization, 
and vaginal dilation may be considered. These patients also need to schedule follow-up 










appointments following discharge to ensure any vaginal adhesions and other complications that 




Ocular Science  
SJS/TEN is commonly accompanied by acute ocular disease, leading to chronic complications. 
Ophthalmology should be involved as early as possible and at the least there should be a 
bedside eye exam within 24-48 hours of disease onset and/or diagnosis. Long-term eye 
morbidity is prevalent even in the absence of defined acute disease and continued regular 
follow-up after discharge is recommended. 
 
Acute ocular involvement presents with eyelid margin inflammation and hyperkeratosis, 
conjunctivitis with membranes/pseudomembranes, as well as corneal/conjunctival epithelial 
defects (which can progress to corneal melt, perforation, or infectious keratitis). Mild disease 
can be managed with topical corticosteroids, antibiotics, frequent administration of lubricants, 
and careful periodic removal of membrane/pseudomembranes. For more severe cases, urgent 
placement of amniotic membrane over the ocular surface within the first week can potentially 
avoid severe debilitating chronic complications [16].   
 
Chronic manifestations include dry eye, eyelid margin keratinization, symblepharon and eyelid 
malposition, chronic conjunctivitis, limbal stem cell deficiency (LSCD), corneal thinning/melt, 
Unmet need: To improve evidence-based approaches to the acute and chronic 
management of SJS/TEN (Table 1). 
 










and infectious keratitis, resulting in discomfort, pain and potential vision loss. Treatment 
options include topical corticosteroids, lubricants, and antibiotics, specialized contact lenses for 
ocular surface protection and visual rehabilitation, eyelid malposition corrective surgery, and 
surgical procedures for LSCD. These include cultivated limbal epithelial cell transplantation 
(CLET), cultivated oral mucosal epithelial transplantation (COMET), and simple oral mucosal 
epithelial transplantation (SOMET). Boston type 1 and 2 keratoprosthesis may be helpful in the 
more severe cases [17]. Though sometimes necessary, outcomes following ocular surface 
surgeries are generally poor in SJS/TEN. As such, recent work has emphasized the importance of 
early intervention with amniotic membrane grafting [18]. This approach may be accomplished 
in a sutureless manner, thus avoiding the necessity to transfer patients to an ophthalmic 
theatre [19]. 
 
Finally, genetic risk factors may be associated with SJS/TEN with “severe ocular complications 
(SOC)” and this warrants further study in particular to prioritize patients for prognostication 
and follow-up. SOC has been linked to “cold-medicines” in some populations with HLA-B*44:03 
(Japanese, Thai, Brazilian, and Indian) and HLA-A*02:06 (Japanese and Korean) [20]. However, it 
has been suggested that these HLA-alleles may rather reflect an infectious trigger than a 
heterogenic group of drugs that were initiated to treat the prodromal symptoms of SJS/TEN 
[21]. A network of susceptibility genes for SJS/TEN (TLR3, EP3, and IKZF1) may trigger the 
inflammation associated with SJS/TEN with SOC (Supplemental Figure S1)[22].  
 
 
Unmet need: To further evidence-based approaches to understanding short- and long-
term mechanisms of morbidity and the prevention and treatment of ocular disease 
associated with SJS/TEN (Table 1). 
 











Updates in Global Regulatory Science, Pharmacovigilance, and Data Mining  
Cases of SJS/TEN and SCAR can be identified from many sources, including post-marketing 
adverse event reporting systems, disease registries, electronic health records (EHRs), literature, 
observational studies, and clinical trials. Cross-sectional studies used EHR allergy lists to identify 
SCAR cases. Causative drugs, including some rarely implicated in SJS/TEN in the literature, and 
differences in patient demographics, were reported [23,24]. An English-language PubMed 
literature search from 1980-2017 yielded 851 cases categorized as “probable” or “definite” 
SJS/TEN cases, 80.6% of which were drug-induced (unpublished data).  
 
In FDA regulatory actions involving labeling for SJS/TEN from 2016-2018, products with SJS/TEN 
labeled in Warnings/Precautions at initial approval or added post-market included 17 
hematology/oncology products, 8 antimicrobials, 6 radiocontrast agents, deflazacort, and 
febuxostat. Post-market reports were the primary source of information for the labeling actions.  
 
The EMA Pharmacovigilance Risk Assessment Committee (PRAC) monitors the Eudravigilance 
database (>50 million records) and uses disproportionality tools (electronic Reaction 
Monitoring Report, eRMR) to identify emerging signals. Since July 2012, PRAC has evaluated 21 
drugs for SCAR risk [25]. From the Eudravigilance data, the fatality of SJS, SJS/TEN overlap and 
TEN is 7.4%, 12.1%, and 22.4%, respectively.  
 










Performance and quality of pharmacogenetic tests assessing SJS/TEN drug-associated risks are 
also regulated by some health authorities; risks to patients with life-threatening diseases of 
treatment decisions based on erroneous testing are also considered. Health Canada’s 
evaluations are becoming more context-aware, placing more emphasis on patients’ needs, real-
world evidence issues and collaborative health system models, which will inform evolutions in 
regulatory science and decisions about pharmacogenetic testing and patient safety. 
 
An example of beneficial impact of regulatory action on reducing SJS/TEN is a “Dear Health Care 
Professional Letter” issued by the Singapore Health Sciences Authority and Ministry of Health in 
2013, advising that genotyping for HLA-B*15:02 would be standard of care in Singapore before 
initiating carbamazepine (CBZ) in new patients of Southeast Asian ancestry. SCAR guides 
highlighted the importance of prompt withdrawal of drugs in suspected SCAR cases. Post-
market reports of CBZ-induced SCAR cases subsequently decreased by >95% [26]. Usage of CBZ 
decreased modestly overall, though new CBZ users declined by 40%. Meanwhile, new users of 
levetiracetam increased 2.7-fold highlighting other factors that have contributed to the 




Prediction, Prevention, Earlier Diagnosis, and Treatment  
A foundation of research to identify predictors of SJS/TEN is careful ascertainment and 
specialist clinical phenotyping, to facilitate accurate diagnosis. In this context, RegiSCAR has 
Unmet need: Studies are needed to leverage large-scale EHR data and advanced 
informatics technology to improve local and international SCAR case-finding methods to 
advance the science of SCAR research (Table 1). 
 










developed an algorithm for assessment of drug causality for epidermal necrolysis (ALDEN), 
which is being used by a number of collaborative networks studying SJS/TEN across genetically 
diverse populations [27]. The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) 
has also developed data collection materials to ensure proper SJS/TEN case ascertainment is 
occurring at each of its centers across Canada. In addition, an algorithm for causality 
assessment has been developed, from which, CPNDS recommendations have been made 
regarding the use of HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of 
carbamazepine-induced hypersensitivity reactions [28]. Genetic studies continue to refine the 
existing scientific knowledge and identify novel predictors of drug-induced hypersensitivity 
reactions (Table 2) [2–5,29–31]. A recent meta-analysis of two genome-wide association studies 
(GWAS) identified HLA-A*31:01 as a strong predictor of both CBZ-induced SCAR and drug-
induced liver injury (DILI) [32]. The same study reported a new association between variation in 
the anaplastic lymphoma kinase (ALK) gene and CBZ-induced SCAR [32].  
 
Another novel report is the association between variation in the complement factor H (CFH) 
gene and phenytoin-induced maculopapular exanthema in individuals of European-ancestry 
[33]. With all the hypersensitivity-related genetic data that is being generated globally, an 
opportunity exists for a large meta-analysis to identify additional predictors and inform 
accurate prevention models. Strong associations have been reported between IL-15 and 
granulysin levels and severity and mortality of SJS/TEN suggesting that these could be utilized in 
earlier identification and prognostication [34,35]. Current suggested interventions and 
therapeutic strategies are highlighted in Supplemental Figure S2. Further prospective, 










randomized controlled studies are needed to provide more definitive conclusions and 




Special Populations  
The etiology, pharmacogenomic risks, epidemiology, clinical features and outcomes of SJS/TEN 
vary considerably in special patient populations. SJS/TEN in children is more frequently non-
drug related; with SJS/TEN very uncommon in the very young (< 2 years old) [36]. SJS/TEN is 
considerably more common (up to 150-fold) in certain immunocompromized patient 
populations, such as patients with cancer and HIV/AIDS [37]. Newer immunomodulatory 
treatments such as the immune checkpoint inhibitors used for treatment of previously 
untreated cancers such as melanoma have been transformative but have been associated with 
severe and unpredictable adverse events. In these populations, there is still much to be learned 
about the clinical presentation and treatment, pre-disposing factors including host genetics, the 
tumor type and the type and combination of immunomodulatory therapy used. Since SJS/TEN 
has been reported several months after the administration of these agents a high index of 
suspicion needs to be maintained. SJS/TEN mortality is higher in the elderly with malignant co-
morbidity (>50%) and pre-existing hepatic disease [37–39].  
 
Although the smaller number of patients in certain subgroups and unclear pathogenesis 
increase difficulties in SJS/TEN research in special populations, pharmacogenomics and 
Unmet need: To fuel discovery and implementation of additional genetic predictors and 
biomarkers for earlier diagnosis and treatment across diverse populations (Table 1). 
 










associated mechanistic studies show promise for predicting SJS/TEN to population relevant 
drugs as was illustrated in the now routine pre-prescription screening of HLA-B*57:01 to 
prevent abacavir hypersensitivity (Table 2) [2]. Large scale therapeutic intervention and long-
term outcome studies should also endeavor to include populations equally balanced across age, 




Beyond Acute Care and Long-term Considerations  
Awareness of SJS/TEN-associated long-term sequelae is increasing. The RegiSCAR study was the 
first to systematically quantify higher mortality, morbidity and lower quality of life (QOL) 
beyond the acute stage by following up a cohort of SJS/TEN survivors at 8±2 weeks, one year 
and five years. At eight-weeks, 88% and 70% of survivors reported skin and eye symptoms 
respectively. These persisted in 77% and 61% at one year, and 73% and 67% respectively at five 
years. Ocular symptoms, reported by patients as the most bothersome, developed despite 
optimal acute care and sometimes only months later. Oral and genital sequelae manifested 
features reflective of localized scarring and functional dryness such as dental caries and genital 
pain, bleeding, dyspareunia, and hypogeusia. Surprisingly, severity of mucosal sequelae did not 
correlate with disease severity in the acute stage (unpublished data) [38].  
 
A pattern of psychological sequelae amongst survivors is also emerging. Clinical criteria for 
anxiety, posttraumatic stress disorder and depression were fulfilled in approximately half, one-
Unmet need: To better understand and personalize approaches to SJS/TEN across the 
heterogeneous populations affected (Table 1). 
 
 










third and one-third respectively in several studies [40,41].  Five years post-discharge, >50% of 
survivors still avoid medication. These long-term sequelae do not only reduce patient’s QOL, 
but also their ability to work. Five years after the acute stage of SJS/TEN, <50% had returned to 
their normal premorbid activities. Approximately 10% of survivors were not back to gainful 
employment after five years compared to 25% at one-year follow-up. (unpublished data) [38]. 
 
Cutaneous scarring and dyspigmentation are common features of SJS/TEN and occur in 46% 
and 77% of cases respectively [42]. The amount of scarring present may be extensive and 
associated with hypertrophic and keloid variants resulting in chronic pain and pruritus [13,43–
45]. The etiology of the scarring is unknown; however, it is possibly impacted by the following: 
delayed re-epithelialization, non-standardized/optimized wound care, differences in systemic 
treatments and comorbid conditions, and genetic predisposition to develop hypertrophic scars.  
 
Conventional treatment options have been adapted from lessons learned by caring for burn 
patients. Common modalities include scar massage, silicone sheeting and the use of pressure 
garments.  While there is evidence that these modalities have been and continue to be helpful, 
there have been many recent advancements in the non-operative management of scarring with 
an emphasis on the use of medical laser devices [46,47]. 
 
More specifically, medical laser devices have been shown to improve scar tissue pliability and 
flexibility leading to improvements in range of motion and symptomatic improvements that can 
result in decreased pain, burning and pruritus. Additionally, restoration of pilosebaceous unit 










functionality with return of sweating and hair growth has been observed. These benefits have 
been achieved predominantly through the use of devices that target hemoglobin and water, 
including the 595nm pulsed dye laser and fractional ablative carbon dioxide lasers. SJS/TEN 
patients with symptomatic and/or disfiguring scarring should be considered for such treatments 
[46,47]. 
 
With increasing awareness, multidisciplinary and system-specific strategies and protocols are 
needed to prevent, diagnose and treat these sequelae. Routine ophthalmic and psychiatric 




Models and Mechanism  
The immunopathogenesis of SJS/TEN remains to be fully elucidated, thus hampering prevention 
and treatment efforts. A major breakthrough arose from the discovery that specific HLA alleles 
predispose and, in most cases, appear necessary but not sufficient for the development of  
SJS/TEN and other SCAR upon exposure to particular drugs, which directly implicated T cells as 
key mediators of disease. Drugs, considered as foreign antigens, likely interact with particular 
HLA/peptide/T-cell receptor (TCR) complexes on keratinocytes to trigger the adaptive immune 
response and adverse reactions. CD8+ cytotoxic T lymphocytes (CTLs), that recognize HLA-drug 
epitopes along with natural killer (NK) and NK T cells infiltrate skin lesions and secrete cytolytic 
proteins/chemokine mediators (e.g. granulysin), causing disseminated keratinocyte death in 
Unmet need: To understand the nature of, prevalence of and risk factors for long-term 
complications and to develop holistic and novel approaches to their management (Table 
1). 
 










SJS/TEN [1]. Multiple predictive genomic markers (Table 2) are subsequently determined to 
prevent drug-specific SJS/TEN and serum biomarkers such as IL-15 and granulysin [34,35] may 
have roles in predicting the prognosis of acute stage SJS/TEN. Single-cell (sc) T-cell receptor 
(TCR) sequencing and repertoire analysis are novel approaches to investigate drug-specific T 
cell populations and can be paired with sc-RNAseq and Cite-seq to examine expression of the 
related transcriptome and proteome of total cell populations on interest [48-49]. Dominant 
TCRαβ clonotypes have been identified in single cells sorted from blister samples of patients 
with HLA-B*58:01 restricted allopurinol-SJS/TEN and HLA-B*15:02 restricted carbamazepine-
SJS/TEN which in the case of the latter represent a public TCRαβ clonotype that is shared 
amongst unrelated HLA-B*15:02 positive patients with carbamazepine SJS/TEN [48-49]. These 
new technologies, combined with traditional analysis of prospectively collected blister fluid, 
skin, and blood, allow the identification of new biomarkers of disease and an avenue to define 
novel and more targeted treatment approaches. The insights generated from these combined 
efforts have led to the development of much-needed mouse models of SJS/TEN and other SCAR. 
A mouse model of abacavir hypersensitivity provides a potential mechanism to explain 
tolerance in the presence of the HLA-B*57:01 risk allele [50]. For SJS/TEN, mouse models have 
allowed for further delineation of disease pathogenesis and provide a system to test potential 
therapeutic interventions [1,50]. Collectively, though much research remains to be done in 




Unmet need: To utilize new technologies and scalable approaches to defining the specific 
immunopathogenesis of SJS/TEN that will lead to biomarkers for prevention, earlier 
diagnosis and treatment (Table 1). 
 










The Patient and Family Perspective 
Most notably, this conference offered an opportunity to identify critical unmet needs within the 
SJS/TEN patient community. Patients described SJS/TEN as a disease that burned their body 
from the inside out, that ravaged and charred their bodies, altered their appearance, and 
wrecked their lives. 
 
From the symptomatic phase through hospitalization and discharge, survivors identified 
multiple gaps in the continuum of care that they felt contributed to the sequelae of SJS/TEN. 
The three most notable areas were diagnosis, acute care management, and discharge care 
plans, discussed in Table 1. 
 
Overall, due to the atypical and rare features of SJS/TEN, many patients and their families felt 
an overwhelming disconnect with the medical community and could only hope that the 
healthcare providers and scientists working together as represented at SJS/TEN 2019 to move 





As the global landscape of treatment for high burden diseases, such as tuberculosis, HIV and 
cancer, evolve, and as an even larger number of new drugs are administered globally, 
increasing concerns arise about the severe adverse drug reactions such as SJS/TEN that 
Unmet need: To develop universal patient-centered approaches to diagnosis, acute 
management and follow-up with significant involvement of patients and survivor groups 
and families in this process (Table 1). 
 










threaten public health and drug safety. The SJS/TEN 2019: From Science to Translation 
conference highlighted how clinical implementation of predictive screening for HLA risk alleles 
before initiating some well-known culprit drugs has made important progress in lowering the 
incidence of SJS/TEN and improving the safety of medication use. In vitro tests, animal models, 
and novel experimental approaches for SJS/TEN research have facilitated a better 
understanding of the causative drugs, the drug-gene interactions, the immune response, and 
the pathogenic mechanisms. Further research is still needed to address the clinical burden, 
epidemiology, drug and population-specific genetic basis and immunopathogenesis of SJS/TEN 
globally. Leveraging existing resources and integrating research networks, registries and clinical 
experts will help facilitate this cause. The ultimate goal is the development of evidence-based 
and personalized approaches to patients with SJS/TEN that will fuel prediction, prevention, and 
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Figure 1. SJS/TEN 2019:  From Science to Translation Conference Participants.  
The SJS/TEN 2019: From Science to Translation conference was organized by the three co-
chairs of the congress: Drs. Elizabeth J. Phillips (Vanderbilt University Medical Center), Bruce C. 
Carleton (University of British Columbia), and Wen-Hung Chung (Chang Gung University). a. 
Global distribution of participants. A total of 164 participants, representing 19 countries across 
six continents, engaged in this meeting, which took place at the British Columbia Children’s 
Hospital Research Institute in Vancouver, Canada. b. Regional Networks and Registries and SJS 
patient support foundations. This was of special significance because it was the largest SJS/TEN 
event that gathered together 16 government representatives, as well as 12 regional SCAR 
networks and registries from countries in North America, Europe, Asia, Africa, and Australia. 
Forty-three local and international SJS/TEN survivors, their families, and local community 
advocacy groups also attended. Six representatives from government drug regulatory and 
research funding agencies in the United States and Canada provided updates on regulatory 
science and funding opportunities related to SCAR and drug safety. c. Each sector shows the 
percentage of each group of participants.  Participants comprised 43 (27%) patient participants, 
29 (18%) dermatologists, 23 (14%) ophthalmologists, 23 (14%) experts in pharmacogenomics or 
clinical pharmacology, 17 (10%) other medical disciplines, 16 (10%) government officers, 10 (6%) 















ABBREVIATIONS USED-  
ADR Adverse drug reaction 
AIDS Acquired immunodeficiency syndrome 
ALDEN Algorithm of drug causality for epidermal necrolysis 
ALK Anaplastic lymphoma kinase 
AUS-SCAR Australian registry of severe cutaneous adverse reactions 
CBZ Carbamazepine 
CFH Complement factor H 
CLET Cultivated limbal epithelial sell transplantation 
COMET Cultivated oral mucosal epithelial transplantation 
CPNDS Canadian Pharmacogenomics Network for Drug Safety 
DILI Drug-induced liver injury 
DRESS Drug reaction with eosinophilia and systemic symptoms 
EHR Electronic health records 
EMA European Medicines Agency 
EpiPGx Epilepsy Pharmacogenomics 
eRMR Electronic Reaction Monitoring Report 
FDA Food and Drug Administration 
GWAS Genome-wide association study 
HIV Human immunodeficiency virus 
HLA Human leukocyte antigen 
IVIg Intravenous immune globulin  










iSCAR International Congress on Cutaneous Adverse Drug Reaction 
ITCH  International Consortium on Drug Hypersensitivity 
LSCD Limbal stem cell deficiency 
MPE Maculopapular eruption 
NATIENS North American Therapeutics in Epidermal Necrolysis Syndrome Network 
PGx Pharmacogenomics 
PMDA Pharmaceuticals and Medical Devices Agency (in Japan) 
PRAC Pharmacovigilance Risk Assessment Committee 
QOL Quality of life 
RegiSCAR Multinational registry of Severe Cutaneous Adverse Reactions to drugs and 
collection of biological samples 
SCAR Severe cutaneous adverse reaction 
SDH Society of Dermatology Hospitalists 
SEAPharm Southeast Asian Pharmacogenomic Network 
SOMET Simple oral mucosal epithelial transplantation 
SJS Stevens-Johnson syndrome 
TB Tuberculosis 
TCR T cell receptor 
TEN Toxic epidermal necrolysis 
TFDA Taiwan Food and Drug Administration 
T-SCAR Taiwan Severe Cutaneous Adverse Reaction Consortium 
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 Improving awareness of physicians and other healthcare providers about SJS/TEN will 
facilitate patient communication, so that patients will have a better understanding of 
this condition. Many feel that healthcare providers are uninformed about SJS/TEN 
and believe it is so rare that they will never see a case. 
 A checklist that would promote early identification and diagnosis of the disease 
should be developed. This would assist physicians and other critical multidisciplinary 
team players, especially those who were never exposed to SJS/TEN patients in their 
pre-clinical and clinical training, to have a heightened suspicion for this disease. 
 An electronic medical record (EMR) that highlights some common causative 
medications and provides decision support to physicians for early identification of the 
potential culprit drug would be helpful.   
 A standard protocol for clinicians including questions about new drug exposure is 
critical to ensure early causality assessment. Ask patients about medications that 
started within the previous 4-6 weeks. This may help confirm or rule out high-risk 
culprit drugs. 
 
Acute Care Management- 
 A streamlined protocol to facilitate earlier transfer of possible SJS/TEN patients to a 
specialized facility with dermatology ward or burn unit and other subspecialty 
assessment for earlier diagnosis and management. 
 In regions where SJS/TEN presents as an unfamiliar disease and lack of available 
expertise, a detailed and accessible checklist outlining care guidelines that includes 
supportive care and education for medical teams, patients, families, and caregivers. 
 The creation of a multidisciplinary team that includes dermatology, ophthalmology, 
gynecology, urology, and pulmonology, gastroenterology, psychiatry, pharmacy, and 
rehabilitation medicine that is established within 24 hours of admission. 
 Protocol to assess and acutely manage the eyes and mucosal tissues to help prevent 
further damage and loss of function. 
 
Discharge- 
 The needs around the discharge process were paramount. Most survivors felt isolated 
in the process, while some felt as if they were sent home to die with little or no 
guidance or confidence in their follow up care with physicians and other healthcare 
workers who were knowledgeable and competent to care for patients with SJS/TEN 
for follow-up care for their future. 
 Recovery from SJS/TEN in physical, mental, and emotional aspects is a gradual, 
ongoing process which requires professional assistance from specialists at different 
stages. Post-traumatic stress disorder-like symptoms are common for survivors who 
are worried about any medication exposure in the future. 










 A holistic post-discharge educational checklist that includes the effect of SJS/TEN not 
only on skin, wounds, eyes and urogenital tract but the potential short and long-term 
implications for health-related quality of life, mental health and recovery. This would 
include a checklist and instructions on recovery care. 
 An “SJS/TEN discharge passport” that includes information on drugs both to avoid and 
safe to take in the future and follow-up appointments with specialists and other 
supportive healthcare resources made prior to discharge. 
 Patients, families, and SJS/TEN advocacy/support groups are eager to participate 
actively in scientific meetings like SJS/TEN 2019, and like being asked questions from 
clinicians and scientists about their experiences to raise attention to this rare but life-
threatening disorder.  




 Education programs and basic training with standardized diagnosis and treatment 
protocols, white papers and clinical practice guidelines are essential and important 
for all healthcare providers and particularly those involved in the diagnosis and care 
of SJS/TEN to gain a better understanding of the early diagnosis and acute and 
chronic clinical care of patients with SJS/TEN. 
 Providing general educational materials, e.g. booklets, handouts, and videos, with 
plain language is a good way to help inform patients; developing support groups and 
creating websites or social media (e.g. Facebook clubs) are also helpful for patients to 
get support from peers. 
 One of the biggest challenges is that some specialists (e.g. dermatologists, allergists, 
ophthalmologists, and gynecologists) might be not available acutely, which increases 
the risk of complications that are permanently disabling.    
 More high-quality and evidence-based research and clinical trials are needed to be 
conducted to help determine best practices for diagnosis and management.  
 
Pharmacogenomics experts’ and basic scientists’ perspective- 
 A global effort to establish a “Network of Networks” to leverage available resources 
and engage multidisciplinary experts, as well as SJS/TEN patients, will help overcome 
limitations (e.g. rarity of condition, small sample sizes, inclusion of all ancestry 
groups) and boost academic development and innovation.   
 The key to SJS/TEN clinical research is precise phenotype adjudication, suggesting that 
standardized, independent case validation is critical.  
 Further investigation is warranted to fulfill the knowledge gap of immunopathogenic 
mechanisms in SJS/TEN patients without prior drug exposure. 
 The lack of stable and sufficient funding useable across international boundaries 
remains one of the major barriers to conducting further studies of global impact and 
maintaining a long-term, productive collaboration.  

















Ethnicity and Carriage 
rate (%) 




(NOT SJS/TEN) [2] 
 European (5~8%) 
 African American (2-3%) 
 Southeast Asian (<1%) 
 Sub-Sahara African 
(<1%) 
 CPIC Level1- High 
 PharmGKB Level2- 
1A 
 U.S FDA3,4- PGx testing 
required 
 Health Canada- PGx testing 
required 
 EMA- PGx testing required 
 PMDA- PGx testing required 





 Southeast Asian (10-
15%) 
 Sub-Sahara African 
(10%)*  
 European (1-6%)* 
 African American (4%) 
 CPIC Level- High 
 PharmGKB Level- 
1A 
 American College of 
Rheumatology guideline- PGx 
testing recommended 
 EMA- PGx testing 
recommended 
 PMDA- Actionable PGx# 
 TFDA- PGx testing 
recommended 
 Singapore- PGx testing is not 
required as a standard of care 
Carbamazepine HLA-B*15:02 SJS/TEN [3,27,31] 
 Asian, particularly Han 
Chinese (10-15%) 
 African (<1%) 
 European (<0.1%) 
 CPIC Level- High 
 PharmGKB Level- 
1A 
 U.S FDA- PGx testing 
recommended 
 Health Canada- PGx testing 
recommended 
 EMA- PGx testing 
recommended 
 PMDA- Actionable PGx 
 TFDA- PGx testing required 
 Singapore- PGx testing 
required 












DRESS and MPE 
[27,31] 
 European (≤6%) 
 Korean (10%) 
 Japanese (18%) 
 Sub-Sahara African 
(<1%) 
 CPIC Level- High 
 PharmGKB Level- 
1A 
 U.S FDA- Actionable PGx 
 Health Canada- PGx testing 
recommended 
 EMA- PGx testing 
recommended 




 Southeast Asian 
(Chinese and Thai 
populations) (2-52%) 
 European (Up to 4%) 
 CPIC Level- Low 
 PharmGKB Level- 
2A 
Not available 
Oxcarbazepine HLA-B*15:02 SJS/TEN [29] 
 Asian, particularly Han 
Chinese (10-15%) 
 African (<1%) 
 European (<0.1%) 
 CPIC Level- High 
 PharmGKB Level- 
1A 
 U.S FDA- PGx testing 
recommended 
 EMA- PGx testing 
recommended 
 PMDA- Actionable PGx 





DRESS and MPE 
[28] 
 European (≤8%) 
 Southeast Asian (≤5%) 
 African (<1%) 
 CPIC Level- High 
 PharmGKB Level- 
1A 




 Asian, particularly Han 
Chinese (10-15%) 
 African (<1%) 
 European (<0.1%) 
 CPIC Level- High 
 PharmGKB Level- 
1A 
 U.S FDA- Actionable PGx 
 Health Canada- PGx testing 
recommended 
 TFDA- Actionable PGx 
Vancomycin HLA-A*32:01 DRESS [30] 
 European (6-7%) 
 African American (3%) 
 Preliminary  
 Single allele testing 
methodology available  
 
CPIC, Clinical Pharmacogenetics Implementation Consortium (https://cpicpgx.org); CYP, Cytochromes P450; DRESS, drug reaction with eosinophilia and 
systemic symptoms; EMA, European Medicines Agency; FDA, Food and Drug Administration; HLA, human leukocyte antigen; MPE, maculopapular eruption; 
PharmGKB, a pharmacogenomics knowledge resource (https://www.pharmgkb.org); PMDA, Pharmaceuticals and Medical Devices Agency in Japan; PGx, 
pharmacogenomics; SJS/TEN, Stevens-Johnson syndrome and toxic epidermal necrolysis; TFDA, Taiwan Food and Drug Administration. 











1The levels of evidence graded by the Clinical Pharmacogenetics Implementation Consortium as defined at https://cpicpgx.org/levels-of-evidence 
2PharmGKB Clinical Annotation Levels of Evidence as defined at https://www.pharmgkb.org/page/clinAnnLevels 
3PharmGKB Drug Label Annotations- https://www.pharmgkb.org/labelAnnotations  
4U.S FDA Table of Pharmacogenomic Biomarkers in Drug Labeling- https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-
biomarkers-drug-labeling; https://www.fda.gov/media/124784/download. 
 
*NPV of HLA-B*58:01 for SJS/TEN and DRESS and Africans and Europeans is lower than Southeast Asians (explains approximately 60% of disease). 
#Actionable PGx- Product labeling includes specific actions to be taken based on the biomarker information. 
 
 
 
 
